Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01081028 · ClinicalTrials.gov registry record
Connect® MM- The Multiple Myeloma Disease Registry
A clinical trial, sponsored by Celgene.
- Terminated
- Registry status
- 3,011
- Enrollment target
NCT01081028: Clinical Trial study, sponsored by Celgene.
NCT01081028 is a clinical trial that was terminated before completion, run by Celgene. The registered enrollment target is 3,011 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01081028 was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- 3,011 participants
- Enrollment target
Study Summary
The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.
Interventions
- OTHER First-line therapy
- DRUG Second-line Multiple Myeloma treatments
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,011 participants |
| Start Date | 2009-09-01 |
| Est. Completion | 2024-12-31 |
Why NCT01081028 stopped before completion
NCT01081028 is an observational study that tracks outcomes without assigning an intervention. Its 3,011 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 2 interventions - of which First-line therapy is the first listed.
NCT01081028 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01081028 about?
NCT01081028 is a clinical study titled "Connect® MM- The Multiple Myeloma Disease Registry". The purpose of the Connect® MM Registry is to explore the natural history and real world management of patients with newly diagnosed symptomatic multiple myeloma (MM) and provide unique insights into the management of MM and the impact of this hematologic disorder on patients.
What is the current status of trial NCT01081028?
This trial is currently terminated. The enrollment target is 3,011 participants. The study started on 2009-09-01. Estimated completion is 2024-12-31.
What interventions are being tested in trial NCT01081028?
The interventions under investigation include: First-line therapy (OTHER), Second-line Multiple Myeloma treatments (DRUG).
Who is sponsoring clinical trial NCT01081028?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00004847 · 3,000 participants · Phase 1
Diagnosis of Pheochromocytoma
- NCT00478712 · 3,000 participants
Hirschsprung Disease Genetic Study
- NCT00579566 · 3,000 participants
Novel Biochemical and Molecular Determinants for Soft Tissue Sarcoma
- NCT00816114 · 3,000 participants
Chart Review Study of Chronic Myelogenous Leukemia (CML) Patients Treated With Imatinib Outside of a Clinical Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI